Pregnancy reports are among the most demanding cases in pharmacovigilance. The event may only appear months after the report, the outcome may be normal, and the people who know most about it are often the hardest to reach.
What counts as a pregnancy report
EU good pharmacovigilance practice includes dedicated guidance on pregnancy and breastfeeding. Reports include exposure of a pregnant woman to a medicine, and also exposure through the father before conception, where relevant to the product. A report may be prospective, meaning the pregnancy was reported before its outcome was known, or retrospective, meaning it is reported after the outcome. Prospective reports are more valuable because they are free of the bias that comes from knowing the result.
Reportable or not
EU guidance distinguishes between an exposure with no adverse event and a report of an adverse outcome. A pregnancy exposure with no associated adverse event is not generally an ICSR, but it should still be followed to outcome, because the absence of an event is only meaningful once the outcome is known. Where there is an adverse outcome, such as a congenital anomaly, spontaneous abortion or foetal death, the case is treated as a suspected adverse reaction and, being serious, follows the 15-day timeline. Congenital anomaly is one of the seriousness criteria. Cases involving the mother’s own reactions, or the infant after birth, are handled as normal cases and linked appropriately.
Follow-up that works
- Send a structured follow-up request promptly, ideally to the healthcare professional who looks after the patient, and always in line with data protection and consent requirements.
- Collect the information that makes the case assessable: dates of exposure relative to the last menstrual period, indication, dose, concomitant medicines, medical and obstetric history.
- Plan follow-up for the expected delivery date and a defined period afterwards, not only for the first request.
- Document attempts that fail. A case lost to follow-up is acceptable if the effort is visible.
Parent and child cases
E2B(R3) allows the relationship between a parent report and a child report to be expressed, which is useful when a mother’s exposure leads to an event in the infant. The structure only helps if the processors use it consistently.
Beyond the individual case
Pregnancy cases feed into periodic safety update reports and risk management plans, where missing information in pregnancy is a common safety concern. If the product is likely to be taken by women of childbearing potential, a pregnancy surveillance approach should be planned from the start, not assembled after the first case arrives.
How PQRA helps
PQRA helps companies write pregnancy follow-up procedures and questionnaires, align them with the product’s risk management plan, and review how pregnancy cases are classified and tracked. We can also assess whether additional surveillance is justified for your product.
Contact PQRA to discuss your pharmacovigilance system, in Greece and across the EU.


No responses yet